



13th European Congress Heroin Addiction & Related Clinical Problems

European Opiate Addiction Treatment Association - EUROPAD



25-27 May 2018

Jagiellonian University

KRAKOW
POLAND-EU



Under the co-patronage of
Santa Chiara University Hospital, Pisa, Italy, EU





EUROPEAN OPIATE ADDICTION TREATMENT ASSOCIATION

EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.

The vision

EUROPAD exists to improve the lives of opiate misusers and their families and to reduce the impact of illicit drug use on society as a whole. The Association works to develop opiate addiction treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes to, addiction treatment worldwide

Scientific Committee of the 13th Congress

Coordinators

Icro Maremmani (Pisa, Italy)
 Marc Reisinger (Brussels, Belgium)

Edward Jacek Gorzelanczyk (Bydgoszcz, Poland)
 Andrej Kastelic (Ljubljana, Slovenia)

Local Scientific Committee*

Tadeusz Marek (Krakow, Poland)
 Irena Roterman-Konieczna (Krakow, Poland)

Marcin Ziółkowski (Bydgoszcz, Poland)
 Piotr Gałęcki (Łódź, Poland)

* under the authority of The Society for the Substitution Treatment of Addiction "Medically Assisted Recovery" Poland - co-organizer of the EUROPAD Conference



International Scientific Committee

Adrian-Octavian Abagiu (Bucarest, Romania)
 Hannu Alho (Helsinki, Finland)
 Marc Auriacombe (Bordeaux, France)
 Michael Farrell (Sydney, New South Wales, Australia)
 Loretta Finnegan (Satellite Beach, Florida, USA)
 Gabriele Fischer (Vienna, Austria)
 Gilberto Gerra (UNODC)
 Milazim Gjocaj (Pristina, Kosovo)
 Liljana Ignjatova (Skopje, Macedonia)
 Ante Ivancic (Porec, Croatia)
 Minja Jovanovic (Kragujevac, Serbia)
 Alexander Kantchelov (Sofia, Bulgaria)
 Mercedes Lovrecic (Ljubljana, Slovenia)
 Angelo G. I. Maremmani (Viareggio, Italy)
 Garrett McGovern (Dublin, Ireland)

Genci Mucullari (Tirana, Albania)
 Lubomir Okruhlica (Bratislava, Slovak Republic)
 Mark Parrino (New York, New York, USA)
 Luis Patricio (Lisbon, Portugal)
 Einal Peles (Tel Aviv, Israel)
 Giulio Perugi (Pisa, Italy)
 Jens Reimer (Hamburg, Germany)
 Marta Torrens (Barcelona, Spain)
 Didier Touzeau (Bagneux France)
 Ambros Uchtenhagen (Zurich, Switzerland)
 Albrecht Ulmer (Stuttgart, Germany)
 Peter Vossenbergh (Deventer, The Netherlands)
 Helge Waal (Oslo, Norway)
 Stephan Walcher (Munich, Germany)
 George Woody (Philadelphia, Pennsylvania, USA)

Under the Patronage of

World Federation for the Treatment of Opioid Dependence, New York, NY, USA
NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)

Jagiellonian University, Krakow, Poland

Santa Chiara University Hospital, Pisa, Italy

Promoted by

European Opiate Addiction Treatment Association

Association for the Application of Neuroscientific Knowledge to Social Aims, Lucca, Italy

The Society for the Substitution Treatment of Addiction - "Medically Assisted Recovery", Poland

Congress Presidents

EDWARD JACEK GORZELANCZYK (Bydgoszcz, Poland)

ICRO MAREMMANI (Pisa, Italy)

Local Scientific Committee

Marcin Ziółkowski -Bydgoszcz, Poland

Piotr Gałeczki - Łódź, Poland

Tadeusz Marek - Krakow, Poland

Irena Roterman-Konieczna - Krakow, Poland



Venue

Jagiellonian University

16 Sw. Lazarza Str. PL 31-530 Kraków, Poland

Phone: +48 12 619-96-02

http://www.cdk.wl.uj.edu.pl/en_GB/

Organizing Committee

Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy

Phone +39 0564412038 - Fax +39 0564412485

E-mail: giusi@tigicongress.com

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy

Phone +39 0584790073 - Fax +39 058472081

E-mail: info@aucns.org

Europad

European Opiate Addiction Treatment Association

Per aspera ad astra

since 1994

Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE



AU - CNS

Association for the Application
of Neuroscientific Knowledge
to Social Aims

Executive Committee

President



Icro Maremmani
(Italy)

Vice President



Marc Reisinger
(Belgium)

General Secretary



Andrej Kastelic
(Slovenia)

EUROPAD2018Krakow

European Opiate Addiction Treatment Association | Congress



World Federation for the Treatment of Opioid Dependence Executive Committee

President



Icro Maremmani
(Italy)

Vice President



Mark W. Parrino
(USA)

Treasurer



Michael Rizzo
(USA)

Corporate Secretary



Marc Reisinger
(Belgium)

PROGRAM

FRIDAY MAY 25, 2018

Room and time	ABSTRACT No	
Room A		SELECTED ORAL PRESENTATIONS
		Europad Selected Presentations <i>Chair: Angelo G.I. Maremmanni (Viareggio, Italy, EU) - Matteo Pacini (Pisa, Italy, EU)</i>
12:00	SOP-01	ADRIAN O. ABAGIU (BUCAREST, ROMANIA, EU) - 5 YEARS OF METHADONE MAINTENANCE TREATMENT IN ARENA OMT CENTER-BUCHAREST
12:20	SOP-02	OLAV DALGARD (Oslo, Norway) - Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies
12:40	SOP-03	OLAV DALGARD (Oslo, Norway) - Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injecting drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
13:00	SOP-04	ALICE DESCHENAU (Villejuif, France, EU) - Addict Assist: a study about acceptability of a questionnaire to assess substance use troubles in a French psychiatric hospital
13:20	SOP-05	JULIA FEIT (Bydgoszcz, Poland, EU) - Disturbances of eyeballs movements in HIV positive and HIV negative opioid addicted individuals before and after the administration of therapeutic dose of methadone
13:40	SOP-06	FELICIA HEIDEBRECHT (London, UK) - Predictors of poor health and heroin use in methadone-treated injecting heroin users: The importance of methadone dosage and crack cocaine use
14:00	SOP-07	BODIL MONWELL (Jönköping, Sweden, EU) - Opiates versus other opioids - are these relevant diagnostics?
14:20	SOP-08	EINAT PELES (Tel Aviv, Israel) - Cannabis use is associated with worse methadone maintenance treatment outcome but not among schizophrenia and other psychotic patients
14:40	SOP-09	OMRI SINAI (Tel Aviv, Israel) - Induced delusional disorder among opiate users: A case report
15:00	SOP-10	JAMIE WILLIAMS (Providence, Rhode Island, USA) - Clinical and psychological interventions in heroin addiction. Spiritual approach for the treatment of opiod addiction

FRIDAY MAY 25, 2018

Room and time	ABSTRACT No	
Plenary Room		PRE-CONFERENCE SYMPOSIA
		1 - Pain management and addiction <i>Chair: Wojciech Leppert (Poznań, Poland, EU)</i>
11:00	PCS1-1	ANNA PRZEKLASA-MUSZYŃSKA (Krakow, Poland, EU) - The current role of cannabinoids in the treatment of chronic pain
11:30	PCS1-2	MAGDALENA KOCOT-KĘPSKA (Krakow, Poland, EU) - Acute pain treatment in opioid tolerant patients
12:00	PCS1-3	RYSZARD PRZEWŁOCKI (Krakow, Poland, EU) - Neurobiology of opioid addiction
12:30	PCS1-4	WOJCIECH LEPPERT (Poznań, Poland, EU) - New possibilities of chronic pain management
Plenary Room		SPECIAL EVENT funded by GILEAD
		1 - Shaping tomorrow together: Changing perceptions of managing HCV in people who use drugs <i>Chair: Carlos Roncero (Salamanca, Spain, EU)</i>
13:00	SE1-1	CARLOS RONCERO (Salamanca, Spain, EU) - Changing perceptions: treating HCV in people who use drugs
13:10	SE1-2	MAGDALENA HARRIS (London, UK) - Perspectives from people living with hepatitis C: how do patients feel?
13:25	SE1-3	VRATISLAV REHAK (Prague, Czech Republic, EU) and CARLOS RONCERO (Salamanca, Spain, EU) - Challenging perceptions: re-thinking treatment of HCV in people who use drugs. Changing perspectives of the liver specialist
13:45	SE1-4	OLAV DALGARD (Lorenskog, Norway) - Changing perceptions: multidisciplinary holistic care can be a reality
14:00		Q&A
14:25		CARLOS RONCERO (Salamanca, Spain, EU) - Meeting summary & close
Plenary Room		SPECIAL EVENT funded by Camurus
		2 - Achieving best outcomes in OUD care. Current challenges, future trends <i>Chair: Gabriele Fischer (Vienna, Austria, EU)</i>
14:30	SE2-1	MIKAEL SANDELL (Stockholm, Sweden, EU) - What is "standard of care in opioid use disorder?" How to achieve this?
14:45	SE2-2	MAURICE DEMATTEIS (Grenoble, France, EU) - Making treatment work in OUD: Practical choices for individuals. What matters must
15:00	SE2-3	LORENZO SOMAINI (Biella, Italy, EU) - Challenges to achieving best outcomes in OUD care. Where are the gaps, what are solutions now and in the future
15:15	SE2-4	GABRIELE FISCHER (Vienna, Austria, EU) - Congress Debate: How should we prepare for the future of OUD care?
Plenary Room		SPECIAL EVENT funded by Molteni
		3 - Levomethadone: a solid pillar for the treatment of opioid addicted patients <i>Chair: Icro Maremmanni (Pisa, Italy, EU) & Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)</i>
15:30	SE3-1	ANGELO G.I. MAREMMANI (Viareggio, Italy, EU) - Overview on treatment access systems across Europe
16:00	SE3-2	STEPHAN WALCHER (Munich, Germany, EU) - Levomethadone: A solid pillar for the treatment of opioid addicted patients
16:30	SE3-3	MARCO RIGLIETTA (Bergamo, Italy, EU) - Real world data: the Italian experience

FRIDAY MAY 25, 2018

Room and time	ABSTRACT No	
Plenary Room		PLENARY SESSION <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i> <i>Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)</i>
17:15		ICRO MAREMMANI (Pisa, Italy, EU) & EDWARD J. GORZELANCZYK (Bydgoszcz, Poland, EU) - Conference Opening
17:30	PS1	MARK PARRINO (New York, NY, USA) - Policy and political dynamics of the opioid addiction crisis in the United States
18:00	PS2	MAURICE DEMATTEIS (Grenoble, France, EU) - Agonist opioid therapeutic strategies: Which treatment for which patients?
18:45	PS3	LORETTA FINNEGAN (Avalon, NJ, USA) - "You've come a long way baby!" Neonatal Abstinence Syndrome and progress over 5 decades
20:00		BREAK
20:30		WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2018 - THE ALESSANDRO TAGLIAMONTE AWARD
		TO BE AWARDED: MAURICE DEMATTEIS (Grenoble, France, EU)
		MATTEO PACINI (Pisa, Italy, EU)
		GABRIELLE WELLE-STRAND (Oslo, Norway)
		CAREER AWARD: MARK PARRINO (New York, NY, USA)



CHIMERA AWARD

European Opiate Addiction Treatment Association Award
"The Alessandro Tagliamonte Award"




"Dedicated to all those who dream of a better world for drug addicts"

FORMER RECIPIENTS:

Marc Auriacombe (France) - 2002
Olof Blix (Sweden) - 2000
Miguel Casas (Spain) - 2012
Thomas Clausen (Norway) - 2014
Pascal Courty (France) - 2012
Jean-Jacques Deglon (Switzerland) - 2004
Sergey Dvoryak (Ukraine) - 2010
Gabriele Fischer (Austria) - 2008
Gilberto Gerra (Italy) - 2006
Ante Ivancic (Croatia) - 2006
Alexander Kantchev (Bulgaria) - 2004
Andrej Kastelic (Slovenia) - 2008
Mercedes Lovrecic (Slovenia) - 2002

Vladimir Mendelevich (Russia) - 2014
Lubomir Okruhlica (Slovak Republic) - 2002
Pier Paolo Pani (Italy) - 2004
Luis Patricio (Portugal) - 2010
Einat Peles (Israel) - 2016
Slavko Sakoman (Croatia) - 2010
Lorenzo Somaini (Italy) - 2014
Marta Torrens (Spain) - 2006
Didier Touzeau (France) - 2008
Ambros Uchtenhagen (Switzerland) - 2016
Peter Vossenbergh (The Netherlands) - 2016
Helge Waal (Norway) - 2012

FORMER CAREER AWARD RECIPIENTS:

Jean-Pierre Daulouede (France) - 2016
Loretta Finnegan (USA) - 2010
Mary Jeanne Kreek (USA) - 2014
Joyce Lowinson (USA) - 2007

Icro Maremmani (Italy) - 2004
Robert Newman (USA) - 2012
Marc Reisinger (Belgium) - 2004
Alessandro Tagliamonte (Italy) - 2004

SATURDAY MAY 26, 2018

Room and time	ABSTRACT No	
Plenary Room		PLENARY SESSION <i>Chair: Marc Reisinger (Brussels, Belgium, EU)</i> <i>Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)</i>
8:30	PS4	MARC AURIACOMBE (Bordeaux, France, EU) - Heroin addiction treatment: What else?
9:15	PS5	RICHARD ROSENTHAL (New York, NY, USA) - The opioid epidemic and the need for new interventions
10:00		COFFEE BREAK
10:30		PARALLEL SYMPOSIA
Plenary Room		1 - Prisoners with substance use disorder and other co-morbidities – medical and human rights considerations <i>Chair: Gabriele Fischer (Vienna, Austria, EU) - Marta Torrens (Barcelona, Spain, EU)</i>
10:30	S01-1	LINDA MONTANARI (Lisbon, Portugal, EU) - Opioid maintenance in European prisons: Is the treatment gap closing? – From a European Perspective
11:00	S01-2	PETER KASTNER (Vienna, Austria, EU) - OPCAT Mandate in Europe highlighting results from Austria in improving accessibility to medical care for prisoners under the legal mandate (2012-2017)
11:30	S01-3	MARI AMOS (Tallin, Estonia, EU) - Preventive Human Rights Protection for prisoners in health issues – an international perspective
12:00	S01-4	ROCIO MARTIN-SANTOS (Barcelona, Spain, EU) - Cost effectiveness and management of hepatitis C treatment in patients with substance use disorder
Room A		2 - Expanding access to buprenorphine treatment <i>Chair: Christopher Welsh (Baltimore, MD, USA)</i>
10:30	S02-1	YNGVILD OLSEN (Baltimore, MD, USA) - Overview of the problem and structural obstacles to implementing change
11:00	S02-2	ERIC WEINTRAUB (Baltimore, MD, USA) - TELE-BUP: prescribing buprenorphine to patients in underserved areas using tele-medicine
11:30	S02-3	CHRISTOPHER WELSH (Baltimore, MD, USA) - Initiating buprenorphine from the emergency department or hospital: capitalizing on the window of opportunity
12:00	S02-4	AARON GREENBLATT (Baltimore, MD, USA) - Telephone consultation to primary care providers: trying to increase prescriber comfort
Room B		3 - Opioid addiction mechanisms <i>Chair: Wojciech Solecki (Krakow, Poland, EU)</i>
10:30	S03-1	WOJCIECH SOLECKI (Krakow, Poland, EU) - Behavioral and molecular endophenotypes of opioid addiction
11:00	S03-2	MICHAŁ KIEŁBIŃSKI (Krakow, Poland, EU) - Ventral tegmental area regulation of cocaine and oxycodone craving
11:30	S03-3	ADAM HAMED (Warsaw, Poland, EU) - Serotonin and glutamate co-transmission in reward anticipation measured by 50-khz ultrasonic vocalization in morphine conditioned context
12:00	S03-4	KAROLINA KARWOWSKA (KRAKOW, POLAND, EU) - Motivational and physiological symptoms of morphine physical dependence - role of adrenergic and corticoid receptor mechanisms

Room and time	ABSTRACT No	
13:30		CONFERENCE LUNCH
14:30		PARALLEL SYMPOSIA - SATURDAY MAY 26, 2018
Plenary Room		4 - Continuity of treatment in Israel <i>Chair: Suzan Ben Ezra (Jerusalem, Israel)</i>
14:30	S04-1	ARTURO G. LERNER (Natania, Israel) - Ayahuasca in the treatment and harm reduction of substance use disorder- Mechanism of action and clinical aspects
15:00	S04-2	SHIRLEY HERTZ-KEISAR (Ness Ziona, Israel) - The new Dual Disorders division – System in progress
15:30	S04-3	ILAN TAL, (Tel Aviv, Israel) - Multi-disciplinary model for prescription opioids misuse in private setting
16:00	S04-4	MICHAEL AMNON (Haifa, Israel) - The connection between resilience and craving among inpatient programs
Room A		5 - Novel psychoactive substances: psychiatric consequences and related behavioural addictions <i>Chair: Rok Tavcar (Ljubljana, Slovenia, EU)</i>
14:30	S05-1	ROK TAVCAR (Ljubljana, Slovenia, EU) - Novel psychoactive substances: what every clinician needs to know about
15:00	S05-2	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Novel synthetic cannabinoids: lessons learned
15:30	S05-3	BARBARA LOVRECIC (Ljubljana, Slovenia, EU) - Novel synthetic cathinones: lessons learned
16:00	S05-4	MOJCA ZVEZDANA DERNOVSEK (Ljubljana, Slovenia, EU) - Assessing, treatment and clinical management of psychiatric consequences of novel psychoactive substances use and related behavioural addictions
Room B		6 - Addictive Disorders: Pre-existing factors and specific psychopathology <i>Chair: Francesco Lamanna (Pisa, Italy, EU)</i>
14:30	S06-1	IACOPO BELCARI (Pisa, Italy, EU) - Are personality disorders pre-existing factors of addictive behaviour?
15:00	S06-2	LUCA ROVAI (Pisa, Italy, EU) - Are affective temperaments pre-existing factors of addictive behaviour?
15:30	S06-3	ANGELO G.I. MAREMMANI (Pisa, Italy, EU) - Towards a specific psychopathology of Substance Use Disorders
16:00	S06-4	ICRO MAREMMANI (Pisa, Italy, EU) - Should emotional responses to life events be included in the specific psychopathology of Substance Use Disorders?
16:30		COFFEE BREAK

Room and time	ABSTRACT No	
17:00		PARALLEL SYMPOSIA, SATURDAY MAY 26, 2018
Plenary Room		7 - Supporting recovery and normalizing life of people in OAT programmes <i>Chair: Andrej Kastelic (Ljubljana, Slovenia, EU) - Liljana Ignatova (Skopje, Macedonia)</i>
17:00	S07-1	LILJANA IGNJATOVA (Skopje, Macedonia) - Stigma and secrecy coping in individuals in treatment for substance dependence in Macedonia and Slovenia
17:30	S07-2	NUSA SEGREC (Ljubljana, Slovenia, EU) - Reducing discrimination - treating difficult to reach populations with mental health and substance use disorders
18:00	S07-3	MIRA DELIC (Ljubljana, Slovenia, EU) - Employability of patients with opioid addiction
18:30	S07-4	ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Ability for driving of people in AOT programmes
Room A		8 - Hot topics in Heroin Use Disorder patients <i>Chair: Thomas Clausen (Oslo, Norway)</i>
17:00	S08-1	EINAT PELES (Tel Aviv, Israel) - Can a measure of heart rate variability serve as a marker for stress among patients in methadone maintenance treatment (MMT)?
17:30	S08-2	MARC REISINGER (Brussels, Belgium, EU) - Opiate addiction treatment and free movement in the Schengen Area : A complaint against Norway
18:00	S08-3	GABRIELLE K. WELLE-STRAND (Oslo, Norway) - How do mothers/parents in opioid maintenance treatment (OMT) do 8-12 years after their child was born?
18:30	S08-4	THOMAS CLAUSEN (Oslo, Norway) - The use of non-prescribed benzodiazepines and/or amphetamines predict treatment instability in opioid maintenance treatment
Room B		9 - Harm reduction in Israel policy, programs and research <i>Chair: Haim Mell (Afula, Israel)</i>
17:00	S09-1	SUZAN BEN EZRA (Jerusalem, Israel) - "A thousand-mile journey begins with one step" - a "first step" for drug and alcohol addicts
17:30	S09-2	HAIM MELL (Afula, Israel) - HIV outbreak related to injection of new psychoactive substances in Tel Aviv, Israel
18:00	S09-3	HAGIT BONNY-NOACH (Ariel, Israel) - Injecting drug use, sex work and differential harm reduction approaches for women: ethnographic study in Israel's largest open drug scene
18:30	S09-4	PAOLA ROSKA (Jerusalem, Israel) - Infectious diseases among OMT patients in Israel - results of a historical cohort study and the new treatment policy
Break-out Room		9B - Multicenter study on opioid misuse before entering Agonist Opioid Treatment in Europe (in collaboration with RADAR system) <i>Chair: Karin McBride (Denver, CO, USA)</i>
19:00		Group meeting (by invitation only)
20:45		SPEAKERS' DINNER* Stara Zajezdnia Kraków by DeSilva - ul. Św. Wawrzyńca 12, 31-060 Kraków
		* Tickets are available for all delegates

SUNDAY MAY 27, 2018

Room and time	ABSTRACT No	
Plenary Room		PLENARY SESSION <i>Chair: Andrej Kastelic (Ljubljana, Slovenia)</i> <i>Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)</i>
9:00	PS6	LORENZO SOMAINI (Biella, Italy, EU) - Treatment efficacy in AOT: the possible role of extended release formulations
10:00		PARALLEL SYMPOSIA
Plenary Room		10 - Hot topics in Heroin Use Disorder patients <i>Chair: Edward Jacek Gorzelańczyk (Bydgoszcz, Poland, EU)</i>
10:00	S10-1	AYMAN MOHSEN FAREED (Dahlonge, GA, USA) - The opioid overdose epidemic in the United States and the utilization of intranasal naloxone to reverse it
10:30	S10-2	EDWARD JACEK GORZELAŃCZYK (Bydgoszcz, Poland, EU) - Addiction and dual diagnosis in perspective of cortico-subcortical loop function
11:00	S10-3	HENRY LOTHANE (New York, NY, USA) - Addiction and humanistic treatment goals
11:30	S10-4	JOLANTA B. ZAWILSKA (Lodz, Poland, EU) - Novel psychoactive substances – new players in the old drama
Room A		11 - Hot topics in Heroin Use Disorder patients <i>Chair: Matteo Pacini (Pisa, Italy, EU)</i>
10:00	S11-1	FRANCINA FONSECA (Barcelona, Spain, EU) - Benzodiazepines use “to get high” in patients admitted for addiction treatment in Spain
10:30	S11-2	MARTIN HARALDSEN (Larvik, Norway) - Agonist opioid treatment (AOT) with buprenorphine (BPN) and often benzodiazepine (BZD) in the GP-setting: Enabling a normalized life
11:00	S11-3	ALEXANDER KANTCHELOV (Sofia, Bulgaria, EU) - The reverse tolerance effect in methadone treated patients
11:30	S11-4	MATTEO PACINI (Pisa, Italy, EU) - Benzodiazepine Use Disorder in patients with and without Opioid Use Disorder
Room B		12 - A new way to think about Dual Disorders: Opioid System and Mental Disorders <i>in collaboration with World Association on Dual Disorder (WADD)</i> <i>Chair: Miguel Casas (Barcelona, Spain, EU)</i>
10:00	S12-1	NESTOR SZERMAN (Madrid, Spain, EU) - Opioid system and Mental Disorders
10:30	S12-2	MARTA TORRENS (Barcelona, Spain, EU) - Mood Disorders and Opioid Use Disorder
11:00	S12-3	CARLOS RONCERO (Barcelona, Spain, EU) - Psychosis and Opioid system
11:30	S12-4	ICRO MAREMMANI (Pisa, Italy, EU) - How to manage Benzodiazepines Use Disorder during methadone treatment

Room and time	ABSTRACT No	
		PARALLEL SYMPOSIA, SUNDAY MAY 27, 2018
Plenary Room		13 - Psychological therapies and interventions in the treatment of opiate use disorder <i>Chair: Alexander Kantchev (Sofia, Bulgaria, EU)</i>
12:00	S13-1	PAUL DELANEY (Dublin, Ireland, EU) - Why a willingness to change is often not sufficient – utilizing motivational interviewing to develop self-efficacy and confidence to change
12:30	S13-2	ALBRECHT ULMER (Stuttgart, Germany, EU) - How to touch the souls of our addicted patients better
13:00	S13-3	ALEXANDER BELCHEV (London, UK) - Integrative therapeutic model of recovery network Turning Point South London, UK
13:30	S13-4	CAROLINE NORMAN (London, UK) - Attachment theory and open dialogue in addictions: How can mentalizing help?
Room A		14 - Hot topics in Substance Use Disorder patients in collaboration with International Society of Addiction Medicine (ISAM) <i>Chair: Riaz Khan (Geneva, Switzerland)</i>
12:00	S14-1	RIAZ KHAN (Geneva, Switzerland) - Public health approach as the basis for addiction policy; the Swiss report on the challenge of addictions
12:30	S14-2	CHRISTOS KOUIMTSIDIS (London, UK) - Could and should cognitive behaviour models being applied across substance misuse groups; are there more differences than commonalities?
13:00	S14-3	ICRO MAREMMANI (Pisa, Italy, EU) - How to manage alcohol use disorder during methadone treatment
13:30	S14-4	LORENZO SOMAINI (Biella, Italy, EU) - Oxytocin in (opioid) addiction: from early discoveries to the present
Room B		15 - Heroin Addiction and Opiate Use Disorder: What else? <i>Chair: Marc Auriacombe (Bordeaux, France, EU)</i>
12:00	S15-1	AMINE BENYAMINA (Villejuif, France, EU) - Opiate use disorder, and other substance uses: What else?
12:30	S15-2	JEAN-PIERRE DAULOUEDE (Bayonne, France, EU) - The goals and conditions for success of opiate addiction treatments in opiate use disorders: What else?
13:00	S15-3	DIDIER TOUZEAU (Bagneux, France, EU) - Prevention of misuse of opiate medications: What else?
13:30	S15-4	MARC AURIACOMBE (Bordeaux, France, EU) - Opiate use disorder, psychiatric comorbidities, dual disorders: What else?
14:00		ICRO MAREMMANI (Pisa, Italy, EU) - Conference Closing and Arrivederci ... a ... May 26-28, 2020



POSTER SESSION

ABSTRACT
No

P-01	SONILA BITRI TIVARI (Tirana, Albania) - Are we missing substance use disorders diagnosis in the emergency department ?
P-02	SONILA BITRI TIVARI (Tirana, Albania) - Alcohol use disorder and heroin addiction. What are the challenges?
P-03	MANUELE GLAUCO CARBONE (Pisa, Italy, EU) - The SCL90-based psychopathological structure may be applied in substance use disorder patients irrespectively of the involved drug also in heroin, alcohol and cocaine mono-drug users
P-04	ELISA CERRAI (Pisa, Italy, EU) - Buprenorphine/Naloxone in add on to psychopharmacological therapy for mood disorder, alcohol and sedative/hypnotics addiction: A case report
P-05	FILIPPO DELLA ROCCA (Pisa, Italy, EU) - Further evidence of a psychopathology specific to Heroin Use Disorder. Relationships between psychopathological dimensions and addictive behaviours
P-06	MAURICE DEMATTEIS (Grenoble, France, EU) - Prevalence of opioid misuse in chronic opioid analgesic therapy for non-cancer pain is high in France
P-07	MARK GILMAN (Manchester, UK) - Lived experience assessment of depot formulations of buprenorphine: opinion of 35 persons with 400 years of combined OUD experience
P-08	BARBARA HAIGHT (Richmond, VA, USA) - RBP-6000 buprenorphine monthly depot demonstrates sustained clinical efficacy and safety in phase III opioid use disorder trials
P-09	FELICIA HEIDEBRECHT (London, UK) - Practitioners' experiences of working with dual users of heroin and crack cocaine. A thematic analysis
P-10	FELICIA HEIDEBRECHT (London, UK) - Differences in treatment outcomes by frequency and drug preference for dual users of heroin and crack in opiate substitution therapy - A pilot study
P-11	DUNCAN HILL (Lanarkshire, UK) - Characteristics of the "revolving door" patients enrolling in the opioid dependence treatment in the EUROPAD - RADARs surveillance initiative
P-12	DUNCAN HILL (Lanarkshire, UK) - Reported gabapentin and pregabalin use by patient enrolling in the opioid dependence treatment in the EUROPAD - RADARs surveillance initiative
P-13	MARION JOUHANNEAU (Villeneuve les Maguelone, France, EU) - Inventory of opiates addiction treatment (OAT) in prisons in France in 2017
P-14	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Excess suicide mortality in Heroin Use Disorder patients seeking Opioid Agonist Treatment in Slovenia and risk factors for suicide
P-15	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Capgras syndrome in a heroin addict. A case study
P-16	CORRADO MANNI (Pisa, Italy, EU) - Atomoxetine and methylphenidate in the treatment of Cocaine Use Disorder in Heroin Use Disorder patients with concomitant Adult ADHD
P-17	SORAYA MAYET (Hull, England, UK) - Effectiveness of opioid overdose and take-home naloxone training for staff
P-18	FADI MEROUEH (Villeneuve les Maguelone, France, EU) - The use of suboxone (buprenorphine and naloxone) in prison
P-19	HEATHER A. OLSEN (Denver, CO, USA) - Comparing prescription opioid use among heroin users using the RADARS® System EUROPAD program
P-20	PASQUALINA ROCCO (Marca Trevigiana, Italy, EU) - Attention Deficit Hyperactivity Disorder in Heroin Use Disorder patients
P-21	ANAT SASON (Tel Aviv, Israel) - Nutrition intervention among methadone maintenance treatment (MMT) patients and food addiction

Neurodevelopment, neuroprogressive and neurodegenerative mood, addictive and psychotic disorders

SAVE THE DATE



Scientific Secretariat

Giulio Perugi, Pisa, Italy, EU
Icro Maremmani, Pisa, Italy, EU

Technical Secretariat

Institute of Behavioural Sciences
G. De Lisio, Pisa, Italy, EU
E-mail: info@iscdelisio.org

PISA-School of Clinical and Experimental Psychiatry
Institute for improving neuroscientific knowledge
ANNUAL MEETING

OCTOBER 22-23, 2018
Hotel Galilei
Pisa, Tuscany, Italy, EU



WADD
World Association
on Dual Disorders
Italian Scientific Committee



WADD
World Association
on Dual Disorders

2ND WORLD CONGRESS
OCTOBER 25-27, 2018
Convitto della Calza
Florence, Tuscany, Italy, EU

CALL FOR PRESENTATIONS
Deadline August 1, 2018

<http://www.europad.org/wadd-conference-2018.php>

Executive Committee

President	Vice President	Secretary	Treasurer
 Prof. Pedro Ruiz (Spain)	 Prof. Miguel Casas (Spain)	 Dr. Nestor Smerman (Spain)	 Prof. Icro Maremmani (Italy)

Technical Secretariat
TIGICONGRESS
Grosseto, Italy
E-mail: giusi@tigicongress.com

Faculty	
Adrian O. ABAGIU	National Institute for Infectious Diseases Prof Dr. Matei Bals (NIIDMB), Bucurest, Romania, EU - [E-Mail: adyaba@gmail.com]
Michael AMNON	Haifa University, Haifa, Israel - [E-Mail: haderech@netvision.net.il]
Mari AMOS	UN Subcommittee on Prevention of Torture, Tallin, Estonia, EU - [E-Mail: mari.amos@gmx.com]
Marc AURIACOMBE	Centre Hospitalier Charles Perrens - Pôle Addictologie - Bordeaux, France, EU - [E-Mail: marc.auriacombe@u-bordeaux.fr]
Iacopo BELCARI	Vincent P. Dole Dual Diagnosis Unit, Department of Specialty Medicine, Psychiatric Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: iacopo.belcari@gmail.com]
Alexander BELCHEV	Turning Point South London, London, UK - [E-Mail: albelchev@gmail.com]
Amine BENYAMINA	Unité d'addictologie de l'hôpital Paul Brousse, Villejuif, France, EU - [E-Mail: abenyamina13@gmail.com]
Sonila BITRI TIVARI	Department of Clinical Toxicology and Addiction, American Hospital, Tirana, Albania - [E-Mail: sonila_bitri@yahoo.com]
Hagit BONNY-NOACH	Ariel University, Ariel, Israel - [E-Mail: hagitbo@gmail.com]
Manuele Glauco CARBONE	School of Psychiatry, University of Pisa, Italy, EU - [E-Mail: manuelglauco carbone@gmail.com]
Elisa CERRAI	Addiction Medicine Clinic, NHS, Pisa, Italy, EU - [elisa.cerai@uslnordovest.toscana.it]
Thomas CLAUSEN	Norwegian Centre for Addiction Research (SERAF), University of Oslo, Norway - [E-Mail: thomas.clausen@medisin.uio.no]
Olav DALGARD	Akershus University Hospital, Akershus University, Oslo, Norway - [E-Mail: ece.kucuksayrac@gilead.com]
Jean-Pierre DAULOUEDE	Centre Hospitalier de la Côte Basque, Bayonne, France, EU - [E-Mail: jeanpierredaulouede@gmail.com]
Paul DELANEY	coAim Sky Business Centre, Dublin, Ireland - [E-Mail: pdelaney3@gmail.com]
Mira DELIC	Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana - [E-Mail: mirjanadelic@yahoo.com]
Filippo DELLA ROCCA	V.P. Dole Research Team, Institute of Behavioural Sciences, Pisa, Italy, EU - [E-Mail: filippo.dellarocca@yahoo.it]
Maurice DEMATTEIS	CHU Grenoble-Alpes, Grenoble, France; INSERM UMR 987, Boulogne Billancourt, France; Hôpital Cochin, Paris, France - [E-Mail: MDematteis@chu-grenoble.fr]
Mojca Zvezdana DERNOVSEK	Educational Institute Mountain, Ljubljana, Slovenia, EU - [E-Mail: mojca_dernovsek@t-2.net]
Alice DESCHENAU	GH Paul Guiraud, Villejuif, France, EU - [E-Mail: alice.deschenau@gh-paulguiraud.fr]
Suzan Ben EZRA	Department of Treatment and Rehabilitation, Israel Anti-Drug Authority, Jerusalem, Israel - [E-Mail: suzanbe@antidrug.gov.il]
Ayman Mohsen FAREED	Mount Sinai Wellness Center, Dahlenega, GA, USA - [E-Mail: ayman.fareed@mtsinaiwelness.com]
Julia FEIT	Non-Public Health Care Center Sue Ryder Home, Bydgoszcz, Poland, EU - [E-Mail: j.feit@domsueryder.org.pl]
Loretta FINNEGAN	The College on Problems of Drug Dependence, Inc., Philadelphia, PA and Finnegan Consulting, Avalon, NJ, USA - [E-Mail: finnegan337@gmail.com]

Francina FONSECA	Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain, EU - [E-Mail: mffonseca@parcdesalutmar.cat]
Mark GILMAN	Discovering Health Ltd, Manchester, UK - [Mark.Gilman@phe.gov.uk]
Edward Jacek GORZELAŃCZYK	Department of Theoretical Basis of Bio-Medical Sciences and Medical Informatics, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland, EU - [E-Mail: medsystem@medsystem.com.pl]
Aaron GREENBLATT	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: agreenbl@som.umaryland.edu]
Adam HAMED	Laboratory of Spatial Memory, Department of Cellular and Molecular Biology, Nencki Institute of Experimental Biology, Polish Academy of Sciences Warsaw, Poland - [E-Mail: a.hamed@nencki.gov.pl]
Martin HARALDSEN	Larvik Municipality - [E-Mail: martinharaldsen@outlook.com]
Magdalena HARRIS	London School of Hygiene and Tropical Medicine, London, United Kingdom [E-Mail: magdalena.harris@lshtm.ac.uk]
Felicia HEIDEBRECHT	London South Bank University, London, UK - [E-Mail: felicias.research@gmx.de]
Shirley HERTZ-KEISAR	Psychiatry Resident, Ness-Ziona – Be'er Yaacov Mental Health Medical Center, Ness Ziona, Israel - [E-Mail: shirleykeisar@hotmail.com]
Duncan HILL	NHS Lanarkshire, UK - [E-Mail: Duncan.hill@lanarkshire.scot.nhs.uk]
Liljana IGNJATOVA	Centre for Prevention and Treatment of Drug Abuse and Addiction, Psychiatric Hospital Skopje, Skopje, Macedonia - [E-Mail: liljana.kiteva.ignjatov@medf.ukim.edu.mk]
Marion JOUHANNEAU	Unité Sanitaire - Maison d'Arrêt de Villeneuve les Maguelone, Villeneuve les Maguelone, France, EU - [E-Mail: f-meroueh@chu-montpellier.fr]
Alexander KANTCHELOV	The Kantchelorov Clinic, Sofia, Bulgaria, EU - [E-Mail: al.kantchelorov@gmail.com]
Karolina KARWOWSKA	Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland, EU - [E-Mail: karolina.m.karwowska@gmail.com]
Andrej KASTELIC	Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana & South Eastern European and Adriatic Addiction Treatment Network, Radomlje Homec, Slovenia, EU - [E-Mail: andrej.kastelic@guest.arnes.si]
Peter KASTNER	Ombudsman Institute Austria, Vienna, Austria - [E-Mail: peter.kastner@volksanwaltschaft.gv.at]
Riaz KHAN	Department of Mental Health and Psychiatry and Department of Primary Healthcare and Community Medicine, University Hospitals of Geneva, Switzerland - [E-Mail: Riaz.Khan@hcuge.ch]
Michał KIEŁBIŃSKI	Institute of Applied Psychology, Jagiellonian University, Krakow, Poland, EU - [E-Mail: michal.kielbinski@uj.edu.pl]
Christos KOUIMTSIDIS	Imperial College London, UK - [E-Mail: drckouimtsidis@hotmail.com]
Magdalena KOCOT-KĘPSKA	Department of Pain Research and Treatment, Medical College, Jagiellonian University, Krakow, Poland, EU - [E-Mail: makoco@wp.pl]
Wojciech LEPPERT	Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland, EU - [E-Mail: wojciechleppert@wp.pl]
Arturo G. LERNER	Lev-Hasharon Mental Health Medical Center, Pardessya, Israel & Sackler School Of Medicine, Tel Aviv University, Ramat Aviv, Israel - [E-Mail: artura@lev-hasharon.co.il]
Henry LOTHANE	Icahn School of Medicine at Mount Sinai, New York, NY, USA - [E-Mail: medsystem@medsystem.com.pl]

Francesco LAMANNA	Addiction Medicine Clinic, NHS, Pisa, Italy, EU - [francesco.lamanna@uslnordovest.toscana.it]
Barbara LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: barbara.lovrecic@nijz.si]
Mercedes LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: mercedes.lovrecic@nijz.si]
Angelo G.I. MAREMMANI	Department of Psychiatry, North-Western Tuscany Region Local Health Unit, Versilian Zone, Viareggio, Italy, EU - [E-Mail: angelogimaremmanni@gmail.com]
Icro MAREMMANI	V.P. Dole Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: icro.maremmanni@med.unipi.it]
Rocio MARTIN-SANTOS	University of Barcelona, Spain - [E-Mail: rmsantos@clinic.ub.es]
Soraya MAYET	Humber NHS Foundation Trust, Hull, England, UK - [E-Mail: smayet@nhs.net]
Haim MELL	Yezreel Valley College, Afula, Israel - [E-Mail: mellhaim@012.net.il]
Fadi MEROUEH	Unité Sanitaire - Maison d'Arrêt de Villeneuve les Maguelone, Villeneuve les Maguelone, France, EU - [E-Mail: f-meroueh@chu-montpellier.fr]
Linda MONTANARI	EMCDDA, Lisbon, Portugal - [E-Mail: Linda.Montanari@emcdda.europa.eu]
Bodil MONWELL	Psychiatric clinic, County Hospital Ryhov/ Jönköping University, Sweden - [E-Mail: bodil.monwell@rjl.se]
Caroline NORMAN	OH Assist, London, UK - [E-Mail: caroline_norman@yahoo.co.uk]
Heather A. OLSEN	Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, USA - [E-Mail: karin.mcbride@rmpdc.org]
Yngvild OLSEN	Johns Hopkins University School of Medicine; Maryland State Department of Health, Baltimore, MD, USA - [E-Mail: Yngvild.olsen1@maryland.gov]
Matteo PACINI	G. De Lisi Institute of Behavioural Sciences, Pisa, Italy - [E-Mail: paciland@virgilio.it]
Mark PARRINO	American Association for the Treatment of Opioid dependence - AATOD, New York, NY, USA - [E-Mail: Mark.Parrino@aatod.org]
Einat PELES	Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment and Research & Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel - [E-Mail: einatp@tlvmc.gov.il]
Anna PRZEKLASA-MUSZYŃSKA	Department of Pain Research and Treatment, Jagiellonian University, Krakow, Poland, EU - [E-Mail: aprzemusz@wp.pl]
Ryszard PRZEWŁOCKI	Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland, EU - [E-Mail: nfprzewl@cyf-kr.edu.pl]
VRATISLAV REHAK	Remedis Clinic, Prague, Czech Republic, EU [E-Mail: rehak@vratislav.cz]
Jens REIMER	Centre for Interdisciplinary Addiction Research, University Medical Centre Hamburg-Eppendorf, Germany, EU - [E-Mail: reimer@uke.de]
Marc REISINGER	EUROPAD & WFTOD, Brussels, Belgium, EU - [E-Mail: m.reisinger@proximus.be]
Marco RIGLIETTA	Department of Drug Addiction, NHS-ASL Bergamo, Italy, EU - [E-Mail: mriglietta@asl.bergamo.it]
Pasqualina ROCCO	Servizio Dipendenze (Sero) U.L.S.S. n.2 Marca Trevigiana, Italy, EU - [E-Mail: pasqualina.rocco@aulss2.veneto.it]
Carlos RONCERO	Psychiatric Service, University of Salamanca Health Care Complex, Salamanca, Spain, EU - [E-Mail: croncero@saludcastillayleon.es]
Richard ROSENTHAL	Stony Brook University Medical Center, Department of Psychiatry and Behavioral Science, Health Sciences Center, Stony Brook, NY, USA - [E-Mail: Richard.Rosenthal@stonybrookmedicine.edu]

Paola ROSKA	Department for the Treatment of Substance Abuse, Ministry of Health, Jerusalem, Israel - [E-Mail: paola.roska@MOH.GOV.IL]
Michael SANDELL	Capio Psykiatri, Capio Maria, Stockholm, Sweden, EU - [mikael.sandell@capio.se]
Anat SASON	Adelson clinic for Drug Abuse Treatment & Research, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel - [E-Mail: anatsas@tlvmc.gov.il]
Nusa SEGREC	University of Ljubljana, Faculty of Medicine, Department of Psychiatry, Ljubljana, Slovenia, EU - [E-Mail: nusa.segrec@psih-klinika.si]
Omri SINAI	Lev Hasharon Medical Center, affiliated to Tel Aviv University, Tel Aviv, Israel - [E-Mail: omrisinai@yahoo.com, ofirliv@gmail.com]
Wojciech SOLECKI	Institute of Applied Psychology, Jagiellonian University, Krakow, Poland, EU - [E-Mail: wojciech.solecki@uj.edu.pl]
Lorenzo SOMAINI	Addiction Medicine Clinic (SerT) Cossano, Biella, Italy, EU - [E-mail: Lorenzo.Somaini@aslbi.piemonte.it]
Nestor SZERMAN	Department of Psychiatry, Hospital General Universitario Gregorio Marañón, Madrid, Spain, EU - [E-Mail: nszermanb@gmail.com]
Ilan TAL	Tal ambulatory Mental Health Center, Tel Aviv, Israel - [E-Mail: drtal@drtal.co.il]
Rok TAVCAR	University Psychiatric Hospital Ljubljana - [E-Mail: rok.tavcar@psih-klinika.si]
Marta TORRENS	IMIM Hospital del Mar Medical Research Institute, Department Neurosciences Research Programme, University of Barcelona, Barcelona, Spain, EU - [E-Mail: mtorrens@parcdesalutmar.cat]
Didier TOUZEAU	Clinique Liberté, Bagneux, France, EU - [E-Mail: didier.touzeau@gmail.com]
Albrecht ULMER	General Practitioner, Stuttgart, Germany, EU - [E-Mail: albrecht.ulmer@gmx.de]
Stephan WALCHER	CONCEPT – Center for Addiction-Medicine, Munich, Germany, EU [kontakt@moviemed.de]
Eric WEINTRAUB	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: eweintra@som.umaryland.edu]
Gabrielle Katrine WELLE-STRAND	SERAF - Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway - [E-Mail: Gabrielle.Katrine.Welle-Strand@helsedir.no]
Christopher WELSH	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: cwelsh@som.umaryland.edu]
Jamie WILLIAMS	Healing Therapy Services, Providence, Rhode Island, USA - [E-Mail: jfwwww1@juno.com]
Jolanta B. ZAWILSKA	Department of Pharmacodynamics Medical University of Lodz, Poland, EU - [E-Mail: jolanta.zawilska@umed.lodz.pl]

Europad		
European Opiate Addiction Treatment Association		
Per aspera ad astra	since 1994	
Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE		AU - CNS Association for the Application of Neuroscientific Knowledge to Social Aims



EUROPAD2018Krakow
 European Opiate Addiction Treatment Association | Congress



Platinum sponsors



MOLTENI
FARMACEUTICI

Golden sponsor

camurus[®]